Type 2 Diabetes Opportunities in Europe "Vast", Says Report

Pharmaceutical Executive

The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan.

The European type 2 diabetes market earned revenues of €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017 (CAGR 3.8 percent), according to new research by Frost & Sullivan.

In the UK, the biggest challenge is the reform of commissioning structures, combined with €40.61 billion efficiency savings, which results in reductions in specialist treatment, says the report.

In Germany, however, the need for a consistent national diabetes plan remains the key area of focus, with “quite a few” new product launches expected in the next two years.

In Southern Europe, Italy, with a focus on integrated diabetes management and care, is likely to bring multiple diabetes services under one roof, addressing issues faced such as long waiting lists, lack of specialized personnel, and adequate medical equipment. Spain, a region where the prevalence of gestational diabetes was as high as 8.8 percent in 2011, has started to introduce telemedicine at hospitals for diabetes care, which is likely to provide faster and improved access treatment.

In the north, Norway, according to the National Diabetes Association, will be dealing over the next two years will include the roll out and financing of the National Strategy for Diabetes as well as the establishment of diabetes registers with cent per cent coverage. Sweden anticipates challenges including the implementation of patient-focused diabetes care, research, and education, while Finland is regarded as the first country in the world to have introduced a comprehensive diabetes program with annual and biennial check-ups provided to patients.

Aiswariya Chidambaram, Healthcare Senior Research Analyst at Frost & Sullivan concludes: “All in all, research advances in novel pathways, such as the neuroendocrine system, will produce next-generation antidiabetic drugs with improved efficacy and safety profiles, creating opportunities for successful market penetration with enhanced and more effective formulations.”

The International Diabetes Federation states that more than 55 million people were diagnosed with diabetes in Europe in 2012, a number that is expected to rise to 64 million by 2030.